Quote:

---

"This partnership with the USAISR and Amarantus allows us to initiate the investigation of the clinical benefits of ESS in patients with an urgent need for the restoration of healthy skin to promote wound healing and improve clinical outcomes," added Joachim Kohn, Ph.D., Principal Investigator of the Rutgers-Cleveland Clinical Consortium of the Armed Forces Institute of Regenerative Medicine, New Jersey Center for Biomaterials, Rutgers University. "While treatment with autografts is most commonly used, it has several limitations including introduction of additional wound sites, increased risk of infection and hypertrophic scarring particularly in patients with large burn areas affecting a major portion of the total body surface. It is my hope that ESS will provide patients with tangible benefits and we are greatly anticipating the launch of the clinical trial."

---

Quote:

---

Joachim Kohn, PhD
Director, RCCC
Rutgers, the State University of New Jersey
Director, New Jersey Center for Biomaterials (njbiomaterials.org)
Board of Governors Professor, Department of Chemistry and Chemical Biology
Adjunct Associate Professor of Orthopaedics, New Jersey Medical School

JOACHIM KOHN is a pioneer in the use of combinatorial and computational methods for the optimization of biomaterials for specific medical applications and is known for his seminal work on "pseudo-poly(amino acid)s". He has published more than 200 scientific manuscripts, holds 40 patents, has spun-off three start-up companies, and has twice received the annual Thomas Alva Edison Patent Award for best patent in New Jersey.

---